EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer

Paul L Swiecicki iD, Emrullah Yilmaz iD, Ari Joseph Rosenberg iD, Takao Fujisawa iD, Justine Yang Bruce iD, Changting Meng, Michele Wozniak, Yongyun Zhao, Michael Mihm, Jason Kaplan iD, Seema Gorla iD, Jessica L Geiger

Journal of Clinical Oncology · 10.02.2025 · 43 (5) · 578-588

DOI: 10.1200/jco.24.00646 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2025. Verfasst von Paul L Swiecicki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Despite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prognosis, and effective treatments are needed. As nectin-4 is widely expressed in HNC, enfortumab vedotin (EV), a nectin-4–directed antibody-drug conjugate, was explored in HNC in EV-202 (ClinicalTrials.gov identifier: NCT04225117 ). METHODS This open-label, multicohort, phase II study evaluated intravenous EV 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle. In the HNC cohort, eligible patients had recurrent/metastatic HNC and had received platinum-based therapy for locally advanced/metastatic disease and a PD-1/PD-L1 inhibitor. The primary end point was investigator-assessed confirmed objective response rate (ORR) per RECIST version 1.1. Secondary end points were investigator-assessed duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS); overall survival (OS); and safety. RESULTS The primary analysis included 46 patients; all received EV (median follow-up, 9.3 months). Most patients (52.2%) had ≥3 previous lines of systemic therapy in the metastatic setting. Confirmed ORR was 23.9%, DCR was 56.5%, and median DOR was not reached (median DOR was 9.4 months at a later data cutoff [median follow-up, 11.3 months]). Median PFS and OS were 3.9 and 6.0 months, respectively. Treatment-related adverse events (TRAEs) occurring in >20% of patients were alopecia (28.3%), fatigue (26.1%), and peripheral sensory neuropathy (23.9%). Sixteen patients (34.8%) experienced grade ≥3 TRAEs; anemia and decreased neutrophil count occurred in ≥1 patient (both n = 2; 4.3%). CONCLUSION EV demonstrated antitumor activity in heavily pretreated HNC. Safety was consistent with the known safety profile of EV; no new safety signals were identified. These data support further evaluation of EV for advanced HNC not amenable to definitive local therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overProgression-Free Survival

Substanzen

Antibodies, Monoclonalenfortumab vedotin

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI.
  • Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
  • Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Pfizer, Bothell, WA.

ORCID-Profile: Paul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg, Takao Fujisawa, Justine Yang Bruce, Jason Kaplan, Seema Gorla

Zitieren

APA

Swiecicki, P. L., Yilmaz, E., Rosenberg, A. J., Fujisawa, T., Bruce, J. Y., Meng, C., Wozniak, M., Zhao, Y., Mihm, M., Kaplan, J., Gorla, S., & Geiger, J. L. (2025). Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. Journal of Clinical Oncology, 43(5), 578-588. https://doi.org/10.1200/jco.24.00646

Vancouver

Swiecicki PL, Yilmaz E, Rosenberg AJ, Fujisawa T, Bruce JY, Meng C, et al. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. Journal of Clinical Oncology. 2025;43(5):578-588. doi:10.1200/jco.24.00646

BibTeX
@article{Swiecicki2025,
  author = {Swiecicki, Paul L and Yilmaz, Emrullah and Rosenberg, Ari Joseph and Fujisawa, Takao and Bruce, Justine Yang and Meng, Changting and Wozniak, Michele and Zhao, Yongyun and Mihm, Michael and Kaplan, Jason and Gorla, Seema and Geiger, Jessica L},
  title = {Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {5},
  pages = {578--588},
  doi = {10.1200/jco.24.00646}
}
Kostenlos starten →